(NASDAQ: ANL) Adlai Nortye's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34%.
Adlai Nortye's earnings in 2026 is -$35,528,000.On average, 4 Wall Street analysts forecast ANL's earnings for 2026 to be -$27,468,184, with the lowest ANL earnings forecast at -$31,752,212, and the highest ANL earnings forecast at -$22,680,152. On average, 3 Wall Street analysts forecast ANL's earnings for 2027 to be -$41,820,280, with the lowest ANL earnings forecast at -$50,568,338, and the highest ANL earnings forecast at -$32,760,219.
In 2028, ANL is forecast to generate -$72,120,483 in earnings, with the lowest earnings forecast at -$105,840,708 and the highest earnings forecast at -$36,540,245.